HUS, Meilahden sairaala

Helsinki FIN-00260

0 studies enrolling now · 5 studies all time

What they study most

Acute Non-cardioembolic Ischemic Stroke, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated), Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, High-risk Transient Ischemic Attack, Lymphoma, Non-Hodgkin, Metastatic Castration Resistant Prostate Cancer (mCRPC), Prevention of Ischemic Stroke

Studies at this site

• A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke — Completed
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) — Stopped early
• Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. — Completed
• First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin — Completed